Effect on health-related quality of life (HRQOL) of adjuvant treatment (tx) with dabrafenib plus trametinib (D plus T) in patients (pts) with resected stage III BRAF-mutant melanoma

被引：3
|
作者：
Schadendorf, Dirk
Hauschild, Axel
Santinami, Mario
Atkinson, Victoria
Mandala, Mario
Chiarion-Sileni, Vanna
Larkin, James M. G.
Nyakas, Marta
Dutriaux, Caroline
Haydon, Andrew
Mortier, Laurent
Robert, Caroline
Schachter, Jacob
Ji, Ran
Aimone, Paola
Manson, Stephanie
Kefford, Richard
Dummer, Reinhard
Kirkwood, John M.
Long, Georgina V.
机构：
[1] Univ Hosp Essen, Essen, Germany
[2] Univ Hosp Schleswig Holstein, Kiel, Germany
[3] Fdn Ist Nazl Tumori, Milan, Italy
[4] Univ Queensland, Princess Alexandra Hosp, Gallipoli Med Res Fdn, Brisbane, Qld 4072, Australia
[5] Papa Giovanni XXIII Canc Ctr Hosp, Bergamo, Italy
[6] Veneto Oncol Inst, Melanoma Oncol Unit, Padua, Italy
[7] Royal Marsden NHS Fdn Trust, London, England
[8] Oslo Univ Hosp, Norwegian Radium Hosp, Oslo, Norway
[9] Ctr Hosp Univ Bordeaux, Hop St Andre, Bordeaux, France
[10] Alfred Hosp, Melbourne, Australia
[11] Univ Lille, INSERM, U 1189, Lille, France
[12] Inst Gustave Roussy, Paris, France
[13] Sheba Med Ctr, Ella Inst Melanoma, Tel Hashomer, Israel
[14] Novartis Pharmaceut, E Hanover, NJ USA
[15] Novartis AG, Basel, Switzerland
[16] Macquarie Univ, Melanoma Inst Australia, Westmead Hosp, Sydney, NSW, Australia
[17] Univ Sydney, Sydney, NSW, Australia
[18] Univ Hosp Zurich, Skin Canc Ctr, Zurich, Switzerland
[19] Univ Pittsburgh, Melanoma Program, Hillman UPMC Canc Ctr, Pittsburgh, PA USA
[20] Univ Sydney, Melanoma Inst Australia, Royal North Shore Hosp, Sydney, NSW, Australia
[21] Univ Sydney, Melanoma Inst Australia, Mater Hosp, Sydney, NSW, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.9590
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9590
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Electronic patient-reported outcomes (ePROs) of adults with BRAF V600-mutant stage III-IV melanoma treated with dabrafenib plus trametinib (D plus T) collected using the Kaiku Health digital patient (pt) monitoring platform
    Lijnsvelt, J.
    Addeo, A.
    Vitale, M. G.
    Mohr, P.
    Queirolo, P.
    Ekstrom, J.
    Vainio, J.
    Kataja, V. V.
    Calado, F.
    Fagan, A.
    Lau, M. R.
    Salas, T. Romero
    Thole-Glettig, H.
    Blank, C. U.
    Ascierto, P. A.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S933 - S934
  • [32] Health-related quality of life analysis in stage III melanoma patients treated with adjuvant dendritic cell therapy
    M. Bloemendal
    M. J. A. Rietveld
    W. W. van Willigen
    W. R. Gerritsen
    C. G. Figdor
    J. J. Bonenkamp
    H. Westdorp
    S. Boudewijns
    R. H. T. Koornstra
    E. M. M. Adang
    G. Schreibelt
    P. B. Ottevanger
    I. J. M. de Vries
    K. F. Bol
    Clinical and Translational Oncology, 2019, 21 : 774 - 780
  • [33] Health-related quality of life analysis in stage III melanoma patients treated with adjuvant dendritic cell therapy
    Bloemendal, M.
    Rietveld, M. J. A.
    van Willigen, W. W.
    Gerritsen, W. R.
    Figdor, C. G.
    Bonenkamp, J. J.
    Westdorp, H.
    Boudewijns, S.
    Koornstra, R. H. T.
    Adang, E. M. M.
    Schreibelt, G.
    Ottevanger, P. B.
    de Vries, I. J. M.
    Bol, K. F.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2019, 21 (06): : 774 - 780
  • [34] Health-related quality of life (HRQoL) in advanced endometrial cancer (aEC) patients (pts) treated with lenvatinib plus pembrolizumab or treatment of physician's choice (TPC).
    Lorusso, Domenica
    Colombo, Nicoletta
    Herraez, Antonio Casado
    Santin, Alessandro
    Colomba, Emeline
    Miller, David Scott
    Fujiwara, Keiichi
    Pignata, Sandro
    Baron-Hay, Sally E.
    Ray-Coquard, Isabelle Laure
    Shapira-Frommer, Ronnie
    Kim, Yong Man
    McCormack, Mary
    Bird, Steven
    Prabhu, Vimalanand S.
    Nguyen, Allison Martin
    Zhao, Qi
    Dutta, Lea
    Makker, Vicky
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [35] Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study
    Bai, Xue
    Shaheen, Ahmed
    Grieco, Charlotte
    d'Arienzo, Paolo D.
    Mina, Florentia
    Czapla, Juliane A.
    Lawless, Aleigha R.
    Bongiovanni, Eleonora
    Santaniello, Umberto
    Zappi, Helena
    Dulak, Dominika
    Williamson, Andrew
    Lee, Rebecca
    Gupta, Avinash
    Li, Caili
    Si, Lu
    Ubaldi, Martina
    Yamazaki, Naoya
    Ogata, Dai
    Johnson, Rebecca
    Park, Benjamin C.
    Jung, Seungyeon
    Madonna, Gabriele
    Hochherz, Juliane
    Umeda, Yoshiyasu
    Nakamura, Yasuhiro
    Gebhardt, Christoffer
    Festino, Lucia
    Capone, Mariaelena
    Ascierto, Paolo Antonio
    Johnson, Douglas B.
    Lo, Serigne N.
    Long, Georgina L.
    Menzies, Alexander M.
    Namikawa, Kenjiro
    Mandala, Mario
    Guo, Jun
    Lorigan, Paul
    Najjar, Yana G.
    Haydon, Andrew
    Quaglino, Pietro
    Boland, Genevieve M.
    Sullivan, Ryan J.
    Furness, Andrew J. S.
    Plummer, Ruth
    Flaherty, Keith T.
    ECLINICALMEDICINE, 2023, 65
  • [36] Updated toxicity profile and relapse-free survival outcomes using an adapted pyrexia management algorithm in patients with resected stage III BRAF V600E/K-mutant melanoma treated with adjuvant dabrafenib plus trametinib in COMBI-APlus
    Del Vecchio, M.
    Atkinson, V. G.
    Ryll, B.
    Menzies, A. M.
    Aubin, F.
    Sileni, V. Chiarion
    Ferraresi, V.
    Lesimple, T.
    Rinaldi, G.
    Saiag, P.
    Robert, C.
    Dutriaux, C.
    Gogas, H. J.
    Demidov, L.
    Gupta, A.
    Banerjee, H.
    Sudhir, S.
    Miranda, F.
    Lau, M. R.
    Grob, J. J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S914 - S914
  • [37] Efficacy of dabrafenib (D) trametinib (T) plus spartalizumab (S) by baseline site of metastases in patients (pts) with previously untreated BRAF V600-mutant unresectable or metastatic melanoma: Post hoc analysis of phase III COMBI-i trial
    Nathan, P.
    Grob, J. J.
    Dummer, R.
    Ascierto, P. A.
    Ribas, A.
    Robert, C.
    Schadendorf, D.
    Flaherty, K. T.
    Tawbi, H. A.
    Hauschild, A.
    Mandala, M.
    Shah, R.
    Banerjee, H.
    Sarkar, R. P.
    Lau, M. R.
    Long, G. V.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S921 - S922
  • [38] A Phase II, Randomised, Open Label Study of Neoadjuvant Pembrolizumab with/without Dabrafenib and Trametinib (D plus T) in BRAF V600 Mutant Resectable Stage IIIB/C/D Melanoma (NeoTrio Trial)
    Gonzalez, M.
    Menzies, A. M.
    Saw, R.
    Thompson, J. F.
    Spillane, A. J.
    Howle, J.
    Nieweg, O.
    Shannon, K.
    Ch'Ng, S.
    Stretch, J. F.
    Carlino, M. S.
    Guminski, A.
    Emmett, L.
    Rizos, H.
    Scolyer, R. A.
    Long, G. V.
    ANNALS OF ONCOLOGY, 2017, 28
  • [39] Real-world health-related quality of life outcomes for patients with resected stage III/IV melanoma treated with adjuvant anti-PD1 therapy
    Egeler, Mees
    Lai-Kwon, Julia
    Tissier, Renaud
    Fraterman, Itske
    Kuijpers, Anke
    Van Houdt, Winan
    Wilgenhof, Sofie
    Rao, Aparna
    Sandhu, Shahneen
    Lee, Rebecca
    Eriksson, Hanna
    van Leeuwen, Marieke
    de Ligt, Kelly
    van Akkooi, Alexander
    van de Poll-Franse, Lonneke
    EUROPEAN JOURNAL OF CANCER, 2024, 200
  • [40] Health-related quality of life (HRQoL) results for adjuvant alectinib vs chemotherapy in patients with resected ALK plus non-small cell lung cancer (NSCLC): Data from ALINA
    Nishio, Makoto
    Wu, Yi-Long
    Barlesi, Fabrice
    Ahn, Jin Seok
    Lee, Dae Ho
    Lee, Jong-Seok
    Zhong, Wenzhao
    Horinouchi, Hidehito
    Hochmair, Maximilian
    Tanaka, Hiroshi
    Glogowski, Maciej
    Rittmeyer, Achim
    Fidler, Mary J.
    Wrona, Anna
    Mamolo, Carla
    Cardona, Andres
    Ruf, Thorsten
    Smoljanovic, Vlatka
    Solomon, Benjamin J.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345